Pancreatic Cancer | Disease Landscape and Forecast | G7 | DLSFON0014-2019

Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is around 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and chemotherapies; thus, demand is high for safer, more-efficacious drugs. FOLFIRINOX and Bristol Myers Squibb’s Abraxane with gemcitabine therapy are cornerstone treatments in the first line. While Merrimack’s Onivyde in combination with 5-FU plus leucovorin has carved out a niche in the second-line setting for patients who failed prior gemcitabine-based therapy; Keytruda is a recommended treatment option in the second line for pancreatic cancer patients with MSI-H or dMMR tumors. However, these therapies offer only modest survival benefits (overall survival is less than one year). AstraZeneca / Merck’s Lynparza is gaining traction as a targeted maintenance therapy for germline BRCA mutations. Although current treatment is dominated by chemotherapies, the pancreatic cancer market is expected to benefit from targeted therapies, mainly kinase inhibitors (Masiviera), monoclonal antibodies (pamrevlumab), biomarker-driven therapies, and launches of novel agents with new mechanisms of action, which will additionally boost market growth over the 2020-2030 forecast period.

Questions answered:

• How large are the clinically and commercially relevant pancreatic adenocarcinoma and pancreatic neuroendocrine tumor (PNET) drug-treatable populations, and how will drug-treatment rates change over the 2020-2030 forecast period?
• What is the current treatment algorithm for pancreatic ductal adenocarcinoma and PNETs in the major markets? What are interviewed experts’ views on current and emerging late-phase therapies?
• Which are the most promising emerging therapies in the late-phase pipeline? What uptake and patient shares can late-phase pipeline agents currently in development for pancreatic cancer expect to secure?
• What are the key drivers and constraints in the pancreatic cancer market, and how will it change in the major markets over the 10-year forecast period?

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 interviews with experts and country-specific surveys with medical oncologists (~30 per country) who treat pancreatic cancer and PNETs.

Epidemiology: Diagnosed and recurrent incidence of renal cell carcinoma by country, segmented by drug-treatable and -treated population and lines of therapy.

Population segments in market forecast: Stage I/II, stage III, first-line, and second-line for metastatic pancreatic adenocarcinoma and pancreatic neuroendocrine tumors.

Emerging therapies: Phase I/II: 12 drugs; Phase III: 6 drugs.

Solution Enhancement

Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.